In Tokyo, researchers have developed a straightforward blood test that reveals what conventional cholesterol measurements miss: whether your body's "good cholesterol" is actually working. The breakthrough, published in April 2026 in the journal Atherosclerosis, measures cholesterol efflux capacity—a marker showing how effectively high-density lipoprotein (HDL) sweeps excess cholesterol from blood vessel walls. The finding matters because it turns out that simply having high HDL levels doesn't guarantee protection against heart disease. What matters is whether that HDL is functioning properly.
Cardiovascular disease kills more people worldwide than almost any other cause, yet predicting coronary artery disease remains stubbornly difficult in clinical practice. Traditional HDL measurements give doctors incomplete information. A patient can have plenty of "good cholesterol" in their blood while still being at risk for a heart attack because the HDL particles aren't removing cholesterol efficiently from the places where plaques form.
Professor Ryunosuke Ohkawa and his team at the Institute of Science Tokyo, working with cardiologist Associate Professor Taishi Yonetsu, tackled this problem by developing a simpler way to measure cholesterol efflux capacity. Their method, called the immobilized liposome-bound gel beads (ILG) method, replaces complex laboratory procedures with something genuinely practical. To test whether it actually works in real patients, the researchers analyzed blood samples and imaging data from 61 patients who had undergone cardiac catheterization examinations at their institution.
The results were striking. Using advanced optical coherence tomography—which visualizes coronary plaques in extraordinary detail—the team compared CEC measurements with the actual characteristics of plaques inside each patient's arteries. Patients with large lipid-rich plaques, the dangerous kind that can rupture and trigger heart attacks, had significantly lower cholesterol efflux capacity. Those with stable, smaller plaques showed higher CEC values. Higher CEC was also linked with HDL particles containing a protein called apolipoprotein E, suggesting this may indicate more protective cholesterol removal.
The implication is transformative. Lower cholesterol efflux capacity appears to indicate unstable, vulnerable plaques—the ones most likely to cause acute coronary syndromes. If doctors can identify these high-risk patients using a simple blood test rather than invasive procedures like cardiac catheterization, they can intervene earlier with preventive treatments.
Until now, cholesterol efflux capacity has been recognized internationally as a promising biomarker but remained largely confined to research laboratories. Existing measurement methods were too complex and cumbersome for everyday clinical practice. By simplifying the measurement through the ILG technique, Ohkawa's team is removing a major barrier to wider use. "By simplifying the measurement of CEC, we aimed to make this biomarker more accessible for clinical use," Ohkawa explained.
The potential is substantial. Identifying patients with reduced HDL function could fundamentally change how doctors assess and monitor cardiovascular risk. Rather than relying on incomplete cholesterol panels, physicians could detect vulnerable plaques in living patients without surgery, guiding more targeted prevention strategies. Looking forward, Ohkawa and his colleagues envision the ILG method contributing to earlier detection of coronary artery disease risk and more precise monitoring of patients after cardiovascular events—turning a laboratory discovery into a tool that could spare lives.